Theodore Huang

Theodore Huang

Auto-generated profile, based on publicly available information

Theodore Huang

Department of Biostatistics Harvard T.H. Chan School of Public Health Boston Massachusetts USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 December 2021 in Cancers
Verified
Journal Article
Open access
PDF file
AMAnne Marie McCarthy
Anne Marie McCarthy
YLYi Liu
Yi Liu
SESarah Ehsan
Sarah Ehsan
ZGZoe Guan
Zoe Guan
JLJane Liang
Jane Liang
JCJinbo Chen
Jinbo Chen
(1) Background: The purpose of this study is to compare the performance of four breast cancer risk prediction models by race, molecular subtype, family history of breast cancer, age, and BMI. (2) Methods: Using a cohort of women aged 40–84 without prior history of breast cancer who underwent screening mammography from 2006 to 2015, we generated breast cancer risk estimates using the Breast Cancer Risk Assessment tool (BCRAT), BRCAPRO, Breast Cancer Surveillance Consortium (BCSC) and combined BRCAPRO+BCRAT models. Model calibration and discrimination were compared using observed-to-expected ratios (O/E) and the area under the receiver operator curve (AUC) among patients with at least five years of follow-up. (3) Results: We observed comparable discrimination and calibration across models. There was no significant difference in model performance between Black and White women. Model discrimination was poorer for HER2+ and triple-negative subtypes compared with ER/PR+HER2−. The BRCAPRO+BCRAT model displayed improved calibration and discrimination compared to BRCAPRO among women with a family history of breast cancer. Across models, discriminatory accuracy was greater among obese than non-obese women. When defining high risk as a 5-year risk of 1.67% or greater, models demonstrated discordance in 2.9% to 19.7% of patients. (4) Conclusions: Our results can inform the implementation of risk assessment and risk-based screening among women undergoing screening mammography.

8 October 2020 in Genetic Epidemiology
Verified
Journal Article
Closed access
PDF file
THTheodore Huang
Theodore Huang
DBDanielle Braun
Danielle Braun
HLHenry T. Lynch
Henry T. Lynch
GPGiovanni Parmigiani
Giovanni Parmigiani

7 June 2020 in Genetic Epidemiology
Verified
Journal Article
Closed access
PDF file
THTheodore Huang
Theodore Huang
MGMalka Gorfine
Malka Gorfine
LHLi Hsu
Li Hsu
GPGiovanni Parmigiani
Giovanni Parmigiani
DBDanielle Braun
Danielle Braun

8 March 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
EBEunchan Bae
Eunchan Bae
JDJulie-Alexia Dias
Julie-Alexia Dias
THTheodore Huang
Theodore Huang
JCJinbo Chen
Jinbo Chen
GPGiovanni Parmigiani
Giovanni Parmigiani
DBDanielle Braun
Danielle Braun
Many pathogenic sequence variants (PSVs) have been associated with increased risk of cancers. Mendelian risk prediction models use Mendelian laws of inheritance to predict the probability of having a PSV based on family history, as well as specified PSV frequency and penetrance (agespecific probability of developing cancer given genotype). Most existing models assume penetrance is the same for any PSVs in a certain gene. However, for some genes (for example, BRCA1/2), cancer risk does vary by PSV. We propose an extension of Mendelian risk prediction models to relax the assumption that risk is the same for any PSVs in a certain gene by incorporating variant-specific penetrances and illustrating these extensions on two existing Mendelian risk prediction models, BRCAPRO and PanelPRO. Our proposed BRCAPRO-variant and PanelPRO-variant models incorporate variant-specific BRCA1/2 PSVs through the region classifications. Due to the sparsity of the variant information we classify BRCA1/2 PSVs into three regions; the breast cancer clustering region (BCCR), the ovarian cancer clustering region (OCCR), and an other region. Simulations were conducted to evaluate the performance of the proposed BRCAPRO-variant model compared to the existing BRCAPRO model which assumes the penetrance is the same for any PSVs in BRCA1 (and respectively BRCA2). Simulation results showed that the BRCAPRO-variant model was well calibrated to predict region-specific BRCA1/2 carrier status with high discrimination and accuracy on the region-specific level. In addition, we showed that the BRCAPRO-variant model achieved performance gains over the existing risk prediction models in terms of calibration without loss in discrimination and accuracy. We also evaluated the performance of the two proposed models, BRCAPRO-variant and PanelPRO-variant, on a cohort of 1,961 families from the Cancer Genetics Network (CGN). We showed that our proposed models provide region-specific PSV carrier probabilities with high accuracy, while the calibration, discrimination and accuracy of gene-specific PSV carrier probabilities were comparable to the existing gene-specific models. As more variant-specific PSV penetrances become available, we have shown that Mendelian risk prediction models can be extended to integrate the additional information, providing precise variant or region-specific PSV carrier probabilities and improving future cancer risk predictions.

9 December 2025 in Statistics in Medicine
Verified
Journal Article
Closed access
JDJulie‐Alexia Dias
Julie‐Alexia Dias
EBEunchan Bae
Eunchan Bae
THTheodore Huang
Theodore Huang
JCJinbo Chen
Jinbo Chen
SGStephen B. Gruber
Stephen B. Gruber
DBDanielle Braun
Danielle Braun